Apr 21, 2025 (PRISM News via COMTEX) --
ReShape Lifesciences (NASDAQ: RSLS), a company focused on weight loss and metabolic health solutions, has received a new U.S. patent allowance for its proprietary diabetes neuromodulation technology--an innovative, non-pharmaceutical approach aimed at managing Type 2 diabetes and hypoglycemia.
The patent, expected to be issued in the coming months, covers a novel method of using targeted electrical pulses to influence nerve activity linked to blood sugar regulation. Notably, this technique uses about 90% less energy than conventional continuous stimulation methods, allowing for longer battery life and the use of smaller, more practical devices.
The core of ReShape’s technology is its vagus nerve modulation system, which strategically stimulates and blocks nerve signals to the pancreas and liver. This dual-action aims to boost insulin production while curbing glucose release, mimicking natural blood sugar regulation with greater precision than traditional treatments.
Preclinical results have shown that the system can match the effectiveness of traditional nerve stimulation while reducing power consumption significantly. The technology is also fully compatible with standard implantable pulse generators, which could streamline development and reduce future production costs.
ReShape CEO Paul Hickey stated that the patent strengthens the company's intellectual property position while supporting future commercialization of its Diabetes Bloc-Stim Neuromodulation (DBSN(TM)) system.
This news follows a prior Notice of Allowance received in March, further underscoring ReShape’s progress in building out a broad platform of patents in neuromodulation, artificial intelligence, and Bluetooth-enabled applications. The company now holds a total of 63 issued or pending patents.
It is also worth noting that ReShape recently entered into an agreement to sell the majority of its assets--including this diabetes technology--to Biorad Medisys, Pvt. Ltd. Upon completion of that deal, ownership of the diabetes neuromodulation system will transfer to Biorad.
The post ReShape Lifesciences Secures New Patent to Advance Non-Drug Diabetes Treatment appeared first on PRISM MarketView.
COMTEX_464772808/2927/2025-04-21T12:07:58
